LifeSci Capital initiated coverage of Oculis (OCS) with an Outperform rating and $55 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target lowered to $29 from $30 at BofA
- 3 Best Stocks to Buy Now, 11/11/2025, According to Top Analysts
- Oculis price target raised to $42 from $36 at H.C. Wainwright
- Oculis Holding: Promising Pipeline Developments and Strong Financial Position Support Buy Rating
- Oculis Holding AG Reports Q3 2025 Financial Progress